FDA updates mifepristone safety study status
Ella Jeffries / beckershospitalreview - The FDA updated its mifepristone guidance, detailing ongoing work on a safety study and the current status of the drug’s Risk Evaluation and Mitigation Strategy program. According to an April 8 news release, the agency said it is still collecting and eval…
AI Summary: The FDA updated the safety review status for mifepristone, yet the regulatory change hasn’t translated into widespread retail availability. Many community pharmacies are still hesitant to dispense the drug due to logistical, legal and reputational concerns, leaving access limited despite federal moves intended to broaden distribution — so yes, policy changed, but practice lagged.
Related Stories
Appeals court curbs mail and telehealth access to mifepristone nationwide / 2 months
FDA weighs easing access to compounded peptides for patients / 2 months
New women's health plan draws criticism for ignoring women's voices / 2 months
FDA to Remove Black Box Warnings from Menopausal Hormone Therapies / 7 months
Supreme Court preserves telehealth and mail access to abortion pill / 1 month
FDA clears first new sunscreen ingredient in two decades / 28 days
FDA commissioner Marty Makary resigns amid mounting scrutiny / 1 month
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Oncology, Novo Nordisk, Pfizer, Supplements and look for the RSS link.
StackHealth Time Machine